A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 1, 2007, Pages 213-220

  Wang, Peipei ^a   Fraser, Heather ^b   Lloyd, Steven G ^a   McVeigh, Jeffrey J ^b   Belardinelli, Luiz ^b   Chatham, John C ^a,c  

^a University of Alabama at Birmingham   (United States)

^b CV THERAPEUTICS INC   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CVT 4325; GLUCOSE; PALMITIC ACID; RANOLAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TISSUE LEVEL; FATTY ACID OXIDATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HEART PERFUSION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETANILIDES; ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CORONARY CIRCULATION; ENZYME INHIBITORS; FATTY ACIDS; GLUCOSE; HEART; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXADIAZOLES; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; VENTRICULAR FUNCTION, LEFT;

EID: 33947431938     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.115519     Document Type: Article

References (34)

1. Belardinelli L, Shryock JC, and Fraser H (2006) The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J 8 (Suppl A):A10-A13.
2. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, and Lathrop DA (2004) Myocardial protection at acrossroads: the need for translation into clinical therapy. Circ Res 95:125-134.
3. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, and Wolff AA (2004a) Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. J Am Med Assoc 291:309-316.
4. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, et al. (2004b) Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43:1375-1382.
5. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, Wolff A, and Sabbah HN (2002) Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 91:278-280.
6. Chatham JC, Gao Z-P, and Forder JR (1999) The impact of 1 wk of diabetes on the regulation of myocardial carbohydrate and fatty acid oxidation. Am J Physiol 277:E342-E351.
7. Clarke B, Wyatt KM, and McCormack JG (1996) Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 28:341-350.
8. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, and Romero G (1998) Metabolic modulation of acute myocardial infarction: The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 98:2227-2234.
9. Elzein E, Ibrahim P, Koltun DO, Rehder K, Shenk KD, Marquart TA, Jiang B, Li X, Natero R, Li Y, et al. (2004) CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability. Bioorg Med Chem Lett 14:6017-6021.
10. Fath-Ordoubadi F and Beatt KJ (1997) Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96:1152-1156.
11. Finegan BA, Lopaschuk GD, Gandhi M, and Clanachan AS (1996) Inhibition of glycolysis and enhanced mechanical function of working rat hearts as a result of adenosine A1 receptor stimulation during reperfusion following ischaemia. Br J Pharmacol 118:355-363.
12. Fragasso G, Piatti PM, Monti L, Palloshi A, Lu C, Valsecchi G, Setola E, Calori G, Pozza G, Margonato A, et al. (2002) Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol 39:413-419.
13. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, and Clanachan AS (2006) Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 41:1031-1038.
14. 2+ overload and LV mechanical dysfunction in ejecting rat hearts. Eur Heart J 26 (Suppl):414.
15. Fraser H, Lopaschuk GD, and Clanachan AS (1999) Alteration of glycogen and glucose metabolism in ischaemic and post-ischaemic working rat hearts by adenosine A1 receptor stimulation. Br J Pharmacol 128:197-205.
16. Fraser H, McVeigh JJ, Ibrahim PN, Blackburn BK, and Belardinelli L (2003) Conditional-dependent effects of CVT-4325, a novel fatty acid oxidation inhibitor, on palmitate utilization. J Am Coll Cardiol 41:253A.
17. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, and Lucchesi BR (1994) Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 28:1231-1237.
18. Lloyd S, Brocks C, and Chatham JC (2003) Differential modulation of glucose, lactate and pyruvate oxidation by insulin and dichloroacetate in the isolated perfused rat heart. Am J Physiol 285:H163-H172.
19. Lloyd SG, Wang PP, Zeng H, and Chatham JC (2004) The impact of low flow ischemia on substrate oxidation and glycolysis in the isolated perfused rat heart. Am J Physiol 287:351-362.
20. Lopaschuk GD and Barr RL (1997) Measurements of fatty acid and carbohydrate metabolism in the isolated working rat heart. Mol Cell Biochem 172:137-147.
21. Lopaschuk GD, Wambolt RB, and Barr RL (1993) An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Therap 264:135-144.
22. MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, Haddock PS, and Karran EH (2003) The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93:e26-e32.
23. Maruyama K, Hara A, Hashizume H, Ushikubi F, and Abiko Y (2000) Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol 52:709-715.
24. Matsumura H, Hara A, Hashizume H, Maruyama K, and Abiko Y (1998) Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Jpn J Pharmacol 77:31-39.
25. McCormack JG, Barr RL, Wolff AA, and Lopaschuk GD (1996) Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93:135-142.
26. McCormack JG, Stanley WC, and Wolff AA (1998) Ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol 30:639-645.
27. Neely JR, Liebermeister H, Battersby EJ, and Morgan HE (1967) Effect of pressure development on oxygen consumption by isolated rat heart. Am J Physiol 212:804-814.
28. Saeedi R, Grist M, Wambolt RB, Bescond-Jacquet A, Lucien A, and Allard MF (2005) Trimetazidine normalizes postischemic function of hypertrophied rat hearts. J Pharmacol Exp Ther 314:446-454.
29. Stanley WC, Hall JL, Hacker TA, Hernandez LA, and Whitesell LF (1997a) Decreased myocardial glucose uptake during ischemia in diabetic swine. Metabolism 46:168-172.
30. Stanley WC, Lopaschuk GD, Hall JL, and McCormack JG (1997b) Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res 33:243-257.
31. Theroux P, Willerson JT, and Armstrong PW (2000) Progress in the treatment of acute coronary syndromes: a 50-year perspective (1950-2000). Circulation 102:IV2-IV13.
32. van der Horst IC, Zijlstra F, van't Hof AW, Doggen CJ, de Boer MJ, Suryapranata H, Hoorntje JC, Dambrink JH, Gans RO, and Bilo HJ (2003) Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 42:784-791.
33. Wang P, Lloyd SG, and Chatham JC (2005) The impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery following low flow ischemia. Circulation 111:2066-2072.
34. Zacharowski K, Blackburn B, and Thiemermann C (2001) Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol 418:105-110.